Abstract
The sedative drug thalidomide ([+]-alpha-phthalimidoglutarimide), once abandoned for causing birth defects in humans1, has found new therapeutic license in leprosy and other diseases, with renewed teratological consequences2. Although the mechanism of teratogenesis3 and determinants of risk remain unclear, related teratogenic xenobiotics are bioactivated by embryonic prostaglandin H synthase (PHS) to a free-radical intermediates that produce reactive oxygen species (ROS), which cause oxidative damage to DNA and other cellular macromolecules4,5. Similarly, thalidomide is bioactivated by horseradish peroxidase, and oxidizes DNA6 and glutathione7, indicating free radical-mediated oxidative stress. Furthermore, thalidomide teratogenicity in rabbits is reduced by the PHS inhibitor acetylsalicylic acid, indicating PHS-catalyzed bioactivation8. Here, we show in rabbits that thalidomide initiates embryonic DNA oxidation and teratogenicity, both of which are abolished by pre-treatment with the free radical spin trapping agentalpha-phenyl-N-t-butylnitrone (PBN). In contrast, in mice, a species resistant to thalidomide teratogenicity, thalidomide does not enhance DNA oxidation, even at a dose 300% higher than that used in rabbits, providing insight into an embryonic determinant of species-dependent susceptibility. In addition to their therapeutic implications, these results constitute direct evidence that the teratogenicity of thalidomide may involve free radical-mediated oxidative damage to embryonic cellular macromolecules.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Lenz, W. A short history of thalidomide embryopathy. Teratology 38, 203–15 (1988).
Castilla, E.E. et al. Thalidomide, a current teratogen in South America. Teratology 54, 273–7 ( 1996).
Stephens, T.D. Proposed mechanisms of action in thalidomide embryopathy. Teratology 38, 229–39 ( 1988).
Wells, P.G. & Winn, L.M. Biochemical toxicology of chemical teratogenesis. Crit. Rev. Biochem. Mol. Biol. 31, 1–40 (1996).
Parman, T., Chen, G. & Wells, P.G. Free radical intermediates of phenytoin and related teratogens. Prostaglandin H synthase-catalyzed bioactivation, electron paramagnetic resonance spectrometry, and photochemical product analysis. J. Biol. Chem. 273, 25079–88 ( 1998).
Liu, L. & Wells, P.G. DNA oxidation as a potential molecular mechanism mediating drug- induced birth defects: phenytoin and structurally related teratogens initiate the formation of 8-hydroxy-2'-deoxyguanosine in vitro and in vivo in murine maternal hepatic and embryonic tissues. Free Radic. Biol. Med. 19, 639–48 (1995).
Arlen, R.R. & Wells, P.G. Extracellular thiol-disulfide status reflecting chemical toxicity mediated via oxidative stress: Validation with paraquat and t-butylhydroperoxide, and implications for phenytoin and thalidomide teratogenicity. FASEB J. 4, A608 (1990).
Arlen, R.R. & Wells, P.G. Inhibition of thalidomide teratogenicity by acetylsalicylic acid: evidence for prostaglandin H synthase-catalyzed bioactivation of thalidomide to a teratogenic reactive intermediate. J. Pharm. Exp. Ther. 277, 1649–58 (1996).
Wells, P.G., Kim, P.M., Nicol, C.J., Parman, T. & Winn, L.M. in Handbook of Experimental Pharmacology Vol. 124, Part I, Ch. 17 (eds. Kavlock, R.J. & Daston, G.P.) 453 –518 (Springer-Verlag, Heidelberg, 1997).
Winn, L.M. & Wells, P.G. Evidence for embryonic prostaglandin H synthase-catalyzed bioactivation and reactive oxygen species-mediated oxidation of cellular macromolecules in phenytoin and benzo[a]pyrene teratogenesis. Free Radic. Biol. Med. 22, 607– 21 (1997).
Kim, P.M. & Wells, P.G. Phenytoin-initiated hydroxyl radical formation: characterization by enhanced salicylate hydroxylation. Mol. Pharm. 49, 172–81 ( 1996).
Cheng, K.C., Cahill, D.S., Kasai, H., Nishimura, S. & Loeb, L.A. 8-Hydroxyguanine, an abundant form of oxidative DNA damage, causes G—-T and A—-C substitutions. J. Biol. Chem. 267, 166–72 ( 1992).
Ashby, J. et al. Thalidomide: lack of mutagenic activity across phyla and genetic endpoints. Mutat. Res. 396, 45– 46 (1997).
Schumacher, H., Smith, R.L. & Williams, R.T. The metabolism of thalidomide: The fate of thalidomide and some of its hydrolysis products in various species. Br. J. Pharmacol. 25, 338–351 ( 1965).
Gordon, G.B., Spielberg, S.P., Blake, D.A. & Balasubramanian, V. Thalidomide teratogenesis: evidence for a toxic arene oxide metabolite. Proc. Nat. Acad. Sci. USA 78, 2545– 8 (1981).
Huang, P.H. & McBride, W.G. Interaction of [glutarimide-2-14C]-thalidomide with rat embryonic DNA in vivo [see comments]. Teratogen. Carcinogen. Mutagen. 17, 1–5 ( 1997).
Neubert, D. Never-ending tales of the mode of the teratogenic action of thalidomide. Teratogen. Carcinogen. Mutagen. 17, i– ii (1997).
Braun, A.G., Harding, F.A. & Weinreb, S.L. Teratogen metabolism: thalidomide activation is mediated by cytochrome P-450. Toxicol. Appl. Pharm. 82, 175–9 (1986).
Hatfill, S.J., Fester, E.D., de Beer, D.P. & Bohm, L. Induction of morphological differentiation in the human leukemic cell line K562 by exposure to thalidomide metabolites. Leukemia Res. 15, 129–36 (1991).
Jonsson, N.A. Chemical structure and teratogenic properties 3. A review of available data on structure-activity relationships and mechanism of action of thalidomide analogues. Acta Pharma. Suec. 9, 521– 42 (1972).
Wuest, H.M., Fox, R.R. & Crary, D.D. Relationship between teratogenicity and structure in the thalidomide field. Experientia 24, 993– 4 (1968).
Kitada, M. & Kamataki, T. Cytochrome P450 in human fetal liver: significance and fetal- specific expression. Drug Metab. Rev. 26, 305–23 ( 1994).
Pottenger, L.H. & Jefcoate, C.R. Characterization of a novel cytochrome P450 from the transformable cell line, C3H/10T1/2. Carcinogenesis 11, 321–7 (1990).
Yang, H.Y., Lee, Q.P., Rettie, A.E. & Juchau, M.R. Functional cytochrome P4503A isoforms in human embryonic tissues: expression during organogenesis. Mol. Pharmacol. 46, 922– 8 (1994).
Winn, L.M. & Wells, P.G. Maternal administration of superoxide dismutase and catalase in phenytoin teratogenicity. Free Radic. Biol. Med. 26, 266–74 ( 1999).
Acknowledgements
These studies were supported by a grant to PGW from the Medical Research Council of Canada. Preliminary reports of this research were presented at the 36th and 38th annual meetings of the Society of Toxicology (USA): Fundam. Appl. Toxicol. 36(S1,P2): 303 (Number 1542), 1997; Toxicol. Sci. 48(1-S): 17 (Number 79), 1999).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Parman, T., Wiley, M. & Wells, P. Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity. Nat Med 5, 582–585 (1999). https://doi.org/10.1038/8466
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/8466
This article is cited by
-
Oxidative stress mediates thalidomide-induced pain by targeting peripheral TRPA1 and central TRPV4
BMC Biology (2020)
-
p63 is a cereblon substrate involved in thalidomide teratogenicity
Nature Chemical Biology (2019)
-
The in vivo developmental toxicity of diethylstilbestrol (DES) in rat evaluated by an alternative testing strategy
Archives of Toxicology (2019)
-
A new target for thalidomide
Nature Chemical Biology (2018)
-
SALL4 mediates teratogenicity as a thalidomide-dependent cereblon substrate
Nature Chemical Biology (2018)